LobbyingXeris Pharmaceuticals lobbying by quarter
Xeris Pharmaceuticals's latest lobbying report covers Q2 2024, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Medical/Disease Research/Clinical Labs.
Xeris Pharmaceuticals
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $10K | 1 |
| Q1 2023 | $10K | 1 |
| Q2 2023 | $10K | 1 |
| Q3 2023 | $10K | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Medical research and clinical labs$40K · 4 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES4 reports
- SENATE4 reports
Firms it paid
| Firm | ||
|---|---|---|
| The Conafay Group | $40K | 7 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/07/19for Q2 2024 | The Conafay Group | Under $5,000 |
| 24/04/19for Q1 2024 | The Conafay Group | Under $5,000 |
| 24/01/22for Q4 2023 | The Conafay Group | Under $5,000 |
| 23/10/20for Q3 2023 | The Conafay Group | $10K |
| 23/07/20for Q2 2023 | The Conafay Group | $10K |
| 23/04/20for Q1 2023 | The Conafay Group | $10K |
| 23/01/20for Q4 2022 | The Conafay Group | $10K |